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Mastoparan, and structurally-related amphipathic peptides, may induce cell death by augmentation of necrotic and/or apoptotic pathways. To
more precisely delineate cytotoxic mechanisms, we determined that [Lys5,8Aib10]mastoparan (mitoparan) specifically induces apoptosis of
U373MG and ECV304 cells, as demonstrated by endonuclease and caspase-3 activation and phosphatidylserine translocation. Live cell imaging
confirmed that, following translocation of the plasma membrane, mitoparan specifically co-localizes with mitochondria. Complementary studies
indicated that mitoparan induces swelling and permeabilization of isolated mitochondria, through cooperation with a protein of the permeability
transition pore complex VDAC, leading to the release of the apoptogenic factor, cytochrome c. N-terminal acylation of mitoparan facilitated the
synthesis of chimeric peptides that incorporated target-specific address motifs including an integrin-specific RGD sequence and a Fas ligand
mimetic. Significantly, these sychnologically-organised peptides demonstrated further enhanced cytotoxic potencies. We conclude that the cell
penetrant, mitochondriotoxic and apoptogenic properties of mitoparan, and its chimeric analogues, offer new insights to the study and therapeutic
induction of apoptosis.
© 2008 Elsevier B.V. All rights reserved.Keywords: Cell penetrating peptides; Apoptosis; Mitochondria; Chimerism; Mastoparan1. Introduction
The mechanism(s) by which the tetradecapeptide mastoparan
(MP, H-INLKALAALAKKIL-NH2) and structural analogues
mediate cell death remains unresolved. Biophysical evidence
indicates that in aqueous solution the structure of MP is largely
disordered, but upon interaction with biological membranes and
lipidic environments MP adopts an amphipathic α-helical con-
formation [1,2]. This ability of MP and its analogues to interact
and insert into biological membranes has prompted a non-Abbreviations: MP, mastoparan; mitP, mitoparan; TUNEL, terminal
deoxynucleotidyl transferase-mediated dUTP nick end labelling; VDAC,
voltage-dependent anion channel; CPP, cell penetrating peptide; PTPC,
permeability transition pore complex
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doi:10.1016/j.bbamcr.2008.01.009specific necrotic model of MP-induced cell death [3]. Accord-
ingly, MP facilitates random pore formation in the plasma
membrane leading to the increased permeability of extracellular
cations and subsequent cell lysis [4]. Conversely, in cell free
systems MP binds specific intracellular targets integral to signal
transduction pathways that orchestrate apoptosis. Cell free mo-
dels of neuronal apoptosis using isolated mitochondria have
shown that MP, through interaction with mitochondrial mem-
branes [5] and opening of mitochondrial permeability transition
pores [6,7], promotes the release of apoptogenic proteins such
as cytochrome c [8], which consequentially leads to activation
of the caspase cascade [8]. The cytotoxic actions of MP have
also been attributed to MP sharing homology with the am-
phipathic helix forming death domains of the tumour necrosis
factor receptor-1 (TNFR-1) and Fas [9].
MP is more widely acknowledged as a receptor-independent,
allosteric regulator of heterotrimeric G proteins, predominantly
Gi and Go. More specifically, MP presents a cationic hydrophilic
Table 1
The predicted masses of all peptides were confirmed to an accuracy of ±1 by
matrix-assisted laser desorption ionization (MALDI) time of flight mass
spectrometry (Kratos Kompact Probe operated in positive ion mode)
Peptide Primary sequence Predicted
mW
Confirmed
mW
MP H-INLKALAALAKKIL-NH2 1478.9 1479.0
mitP H-INLKKLAKL(Aib)KKIL-NH2 1617.1 1617.9
Z-Gly-RGDf-
mitP
Z-GRGDf INLKKLAKL(Aib)
KKIL-NH2
2273.8 2274.0
Z-Gly-RGEf-
mitP
Z-GRGEf INLKKLAKL(Aib)
KKIL-NH2
2287.9 2288.1
WEWT(Ahx)
mitP
H-WEWT(Ahx)INLKKLAKL(Aib)
KKIL-NH2
2322.8 2322.3
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protein binding domain of G protein-coupled receptors [1,2,
10,11]. However, the cytotoxic action of MP is probably inde-
pendent of pertussis toxin (PTX)-sensitive G proteins (Gi/Go)
[12] and there is growing evidence to suggest that the diverse
biological properties of MP are not restricted to those events
regulated by heterotrimeric G proteins [13]. This phenomenon is
particularly relevant to its chimeric analogues [13] and espe-
cially the relatively inert cell penetrant MP chimera transportan
10 that is widely employed as an effective peptide vector [14].
The ex vitro characteristics of MP, as a facilitator of mito-
chondrial permeability transition, has lead to proposals that MP
could be of utility in cancer therapeutics [15], provided that MP
is encapsulated in a tumour-selective delivery system. Features
of such a construct would necessitate cell penetration in addition
to specific tumour homing properties. We have recently re-
ported that our highly efficacious MP analogue [Lys5,8Aib10]
MP (mitoparan; mitP) promotes a concentration-dependent de-
crease in U373MG astrocytic tumour cell viability [16]. Thus,
one major aim of the present study was to confirm that mitP
penetrates the plasma membrane of both U373MG astrocytoma
and ECV304 bladder carcinoma cells, and to identify intra-
cellular loci of action that subsequently induce apoptotic events
in these cancer cell lines.
A rapidly expanding field of peptide and cell penetrating
peptide research has been dedicated to the selective targeting of
tumours by engineering constructs that incorporate cell-specific
or tissue-specific address motifs [17,18]. Peptidyl address motifs
could enhance the selectivity of drug delivery leading to a
probable reduction in non-selective side effects, whilst the im-
proved cellular uptake offered by cell penetrating peptides
(CPP), undoubtedly enhances bioavailability. The utility of mitP,
as a novel cell penetrant mitochondriotoxic peptide, was thus
further studied by analysis of the cytotoxic profiles of chimeric
peptides that incoporated peptidyl address motifs as N-terminal
extensions. These investigations included an RGD motif which
confers an ability to selectively bind cell adhesion receptors
(integrins) [19]. Phage display technologies have also identified
RGD as a glioma-specific ligand [20], whilst integrin αVβ3
expressed on ECV304 cells binds extracellular matrix compo-
nents in an RGD-dependent manner [21]. Additionally, these
studies also included the more recently described Fas ligand
mimetic sequence WEWT, since this tetrameric sequence could
bind Fas to activate the extrinsic apoptotic pathway [22,23].
Our adopted chimeric strategy may also be referred to as
a sychnologic organisation, a term originally adopted by Sch-
wyzer [24] to describe the organisation of recognition elements
of peptide hormones. The main diagnostic feature of synchno-
logic peptides is the spatial separation of address and message
motifs that are themselves continuous in nature. However, it
is not uncommon that N-terminal extension or covalent at-
tachment with an address motif may severely impact upon the
bioactivity of the message. Thus, a second objective of this
study was to establish that the desirable pharmacodynamic
parameters of mitP can be incorporated as a component of
chimeric target-selective peptides without abrogation of cyto-
toxic efficacy.2. Materials and methods
2.1. Materials
N-α-tert-Butyloxycarbonyl-Cys(3-Nitro-2-pyridinesulfanyl)-OH (Boc-Cys
(Npys)-OH), Mas17 and cyclo(-RGDfV) were purchased from Bachem (St.
Helens, UK). All other materials for solid phase peptide synthesis were from
Novabiochem (Beeston, UK). Cell culture medium was obtained from PAA
Laboratories Ltd (Linz, Austria). All other chemical reagents were purchased
from Sigma Aldrich (Dorset, UK) unless otherwise stated.
2.2. Peptide synthesis, purification and analysis
With the exception of Mas17 and cyclo(-RGDfV), peptides were manually
synthesized (0.1 mmol scale) on Rink amide methylbenzhydrylamine (MBHA)
resin employing an N-α-Fmoc protection strategy with 2-(1-H-Benzotriazole-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/N-Hydroxybenzotria-
zole) (HBTU/HOBt) activation. Crude peptides were purified to apparent
homogeneity by semi-preparative scale HPLC [25]. Fluorescent peptides, to be
used in confocal live cell imaging, were synthesized by N-terminal acylation
with 6-carboxy-tetramethylrhodamine or 5-carboxy-fluorescein (Novabio-
chem, Beeston, UK). The predicted masses of all peptides used (average M+
H+) were confirmed to an accuracy of +1 by matrix-assisted laser desorption
ionization (MALDI) time of flight mass spectrometry (Kratos Kompact Probe
operated in positive ion mode).
2.3. Cell culture
U373MG cells were maintained in DMEM and ECV304 cells in M199 in a
humidified atmosphere of 5% CO2 at 37 °C. Both media contained L-glutamine
(0.1 mg/ml) and were supplemented with 10% (wt/vol) fetal bovine serum
(FBS), penicillin (100 U/ml) and streptomycin (100 µg/ml).
2.4. MTT assays of cellular viability
Cell viability was measured by the 3-(4,5-dimethylthazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) conversion assay [26]. U373MG and ECV304 cells
were cultured as above in 96 well plates and washed in medium without serum
prior to assay. Cells were treated with MP, mitP and chimeric analogues at 37 °C
for the times indicated and further incubated with MTT (0.5 mg/ml) for 3 h at
37 °C. The insoluble formazan product was solubilized with DMSO. MTT
conversion was determined by colorimetric analysis at 540 nm. Cell viability
was expressed as a percentage of those cells treated with vehicle (medium)
alone. Graphical representations of changes in cell viability and LD50 values
were calculated using GraphPad Prism 5 software and the sigmoidal dose–
response function. Statistical analyses were performed using the non-parametric
Mann–Whitney U test; set parameters were one-tailed from unpaired
observations with confidence intervals set at 95% (GraphPad Prism 5).
Fig. 1. Temporal analyses of mitP-induced cytotoxicity. U373MG (A) and ECV304 cells (B) were exposed to varying concentrations of mitP (0.1–30 µM) for the time
periods indicated. Cell viability was used to determine cytotoxicity and measured by MTT conversion. Cell viability was expressed as a percentage of those cells
treated with vehicle (medium) alone. Data points are mean±S.E.M. from 3 experiments performed in triplicate.
Table 2
LD50 values were calculated for all peptides using Graphpad Prism software
Peptide LD50
ECV304 U373MG
MP 30.26±0.05 26.49±0.04
MitP 6.81±0.05 7.92±0.12
Z-Gly-RGDf-mitP 1.40±0.13 4.79±0.16
Z-Gly-RGEf-mitP 4.71±0.05 7.45±0.03
Z-Gly-RGDf-mitP1 6.08±0.08 4.87±0.83
Z-Gly-RGDf-mitP+cyclo(-RGDfV)1 9.17±0.07 10.27±2.5
WEWT(Ahx)mitP 4.44±0.04 28.10±0.03
Data are expressed in µM as mean±S.E.M. from 3 separate experiments. Values
were calculated following 24 h exposure to peptides. Exceptions are highlighted
(1) where cell viability readings were measured following 2 h, a time point
optimized for the addition of cyclo(-RGD-DPhe-Val) (300nM) without evidence
of cellular detachment.
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Nuclear DNA fragmentation, a characteristic of apoptosis, was detected by the
Tdt (terminal deoxynucleotidyl transferase)-mediated dUTP nick end labeling
(TUNEL) assay according to manufacturers instructions (In Situ Cell Death
Detection kit, TMR red, Roche, UK). U373MG and ECV304 cells were grown to
sub confluence on cover slips in 6 well plates, washed and treated with peptides or
vehicle alone (medium) for 2 h in medium without serum. Cells were washed with
phosphate-buffered saline (PBS), pH 7.4 and fixed with 4% (wt/vol) formaldehyde
in PBS for 1 h at room temperature. Fixed cells were permeabilizedwith 0.1% (vol/
vol) Triton X-100 in 0.1% (wt/vol) sodium citrate at 4 °C for 2 min, then incubated
for 1 h at 37 °C in a humidified atmosphere in the dark with TUNEL reaction
mixture containing Tdt and TMR red-dUTP to label free 3′OH ends in the DNA.
Cover slips were washed in PBS, air-dried and mounted on slides with
Vectashield™ (Vector Laboratories Inc, Peterborough, UK) containing 4′6′
Diamidino-8-phenylindole dihydrochloride (DAPI) to counter stain double-
stranded DNA in the nuclei. Samples were analyzed using a Carl Zeiss LSM
510 Meta confocal microscope. Positive controls were achieved by incubating
fixed and permeabilized cells with DNase 1, grade 1 (3000 U/ml in 50 mM Tris–
HCl, pH 7.5, 1mg/mlBSA) for 10min at room temperature to inducedDNA strand
breaks, prior to labeling procedure. Negative controls were achieved by incubating
fixed and permeabilized cells in TUNEL reaction mixture without Tdt.
2.6. Confocal Microscopy, fluorescence detection and co-localization
studies
Cells were plated out into 35 mm sterile glass base dishes (IWAKI, Japan) and
grown to subconfluence in medium containing 10% (vol/vol) fetal bovine serum
(FBS) and penicillin (100U/ml) and streptomycin (100 µg/ml) andmaintained in a
humidified atmosphere of 5%CO2 at 37 °C. Growingmediumwas gently removed
and cells were washed once in pre-warmed stimulation medium (without phenol
red, serum and penicillin streptomycin). Cells were incubated with fluorescent
peptides diluted to a final concentration of 5 µM in stimulation medium, for the
indicated time periods and at 37 °C in a humidified atmosphere of 5% CO2. Cells
were washed gently, 8 times in stimulation medium and incubated in 1 ml
stimulation medium for the duration of the analysis. Cells were analyzed using aCarl Zeiss LSM 510Meta confocal microscope. For mitochondrial co-localization
studies, cells were incubated with 200 nM Mitotracker® Green FM (Molecular
Probes, Invitrogen, Paisley, UK) alongside fluorescent peptides. Quantitative co-
localization was performed using the Carl Zeiss quantitative co-localization
analysis software, incorporating an interactive scatter plot and data table linked to
the images. Pixels showing an intensity above the background of both channels
(background defined as, pixels in channel 1 only, e.g. rhodamine and pixels in
channel 2 only, e.g. fluorescein) were designated as co-localized pixels. Data were
collected from an average of 12 regions of interest, between 50–200 µm2 and from
3 independent experiments. Co-localization (coloc) coefficients were calculated for
the two different fluorophores according to the following equations: C1=pixels
channel 1 coloc/pixels channel 1 total, C2=pixels channel 2 coloc/pixels channel 2
total and defined as relative number of co-localizing pixels in channel 1(designated
rhodamine) or 2 (designated fluorescein), respectively, as compared to the total
number of pixels above threshold. Overlap coefficients after Manders were also
used to quantify co-localization. Coefficients generated values between 0 and 1. A
852 S. Jones et al. / Biochimica et Biophysica Acta 1783 (2008) 849–863value of 0 indicated no co-localization, whereas a value of 1 indicated that all pixels
were co-localized.
2.7. Measurement of caspase-8 activity
Caspase-8 activity was measured using the Caspase-8 Colorimetric Assay (R
&DSystems, Abingdon,UK) according tomanufacturers instructions. U373MG
and ECV304 cells were cultured as above and distributed to 6 well plates to give
2×106 cells per well and exposed to peptides, diluted in stimulation media orvehicle (media alone), for the indicated time periods. Reactions were terminated
by the addition of 100 µl ice-cold lysis buffer (R & D Systems, Abingdon, UK).
Cell lysates were centrifuged for 1 min at 10,000 ×g at 4 °C. Supernatants (50 µl)
were transferred to a 96 well plate and incubated with 5 µl of caspase-8 co-
lorimetric substrate conjugated to p-nitroanaline (IETD-pNA) and 50 µl reaction
buffer (R & D Systems, Abingdon, UK) at 37 °C for 2 h. Absorbances were read
on a microtitre plate reader at 405 nm and caspase-8 activity expressed as fold/
basal. A recombinant caspase-8 enzyme (R & D Systems, Abingdon, UK) was
used as a positive control.
Fig. 2. MitP induces apoptosis as confirmed by DNA fragmentation and
activation of caspase-3. (A) U373MG and ECV304 cells were treated with mitP
(10 µM) or vehicle alone for 2 h. Cells were fixed in 4% (wt/vol) formaldehyde
and permeabilized with 0.1% (vol/vol) Triton X-100. Nuclear DNA fragmenta-
tion, indicative of apoptosis, was detected by TUNEL in situ cell detection assay,
TMR red (Roche) and cells were counterstained with DAPI to visualize nuclear
DNA. Representative examples are shown. The appearance of TMR red fluo-
rescence located in the nuclei of mitP-treated cells provides evidence of
apoptosis, whereas DNA fragmentation is not evident in cells treated with
vehicle alone (vehicle). Fixed and permeabilized cells were incubated with
Dnase 1 (3000 U/ml) to induce DNA strand breaks, prior to the labeling pro-
cedure and therefore acts as a positive control (Dnase 1). DNA fragmentation is
comparable to cells treated with mitP. As a negative control, fixed and per-
meabilized cells were treated with labeling solution without terminal deoxy-
nucleotidyl transferase (−Tdt). Bars are 20 µm. (B) U373MG and ECV304 cells
were treated with mitP (10 µM) or vehicle alone for 1 h. DEVD-NucView™ 488
Caspase-3 Substrate (Biotum, Inc) was added at a final concentration of 5 µM
for a further 30 min and cells viewed by confocal live cell imaging. The cell
permeable construct DEVD-NucView™ 488 Caspase-3 Substrate consists of a
functional high affinity DNA-binding dye that is rendered inert by the highly
negatively charged DEVD peptide substrate. Upon activation of caspase-3, the
substrate is cleaved to release a functional DNA dye that subsequently migrates
to the nucleus. Green fluorescence seen in the nuclei of mitP-treated cells
indicates activation of caspase-3, compared to cells treated with medium alone
(vehicle). (C) Flow cytometric analysis of annexin-V-fluorescein and propidium
iodide (PI) staining of ECV304 and U373MG cells treated with mitP (10 µM).
Quadrant statistics from 4 separate experiments were combined, represented
graphically and demonstrate a predominant cell population of annexin-V+/PI−
(early apoptotic) compared to annexin-V+/PI+ (necrotic). Annexin-V−/PI+ repre-
sent dead cells and annexin-V−/PI− represent viable cells.
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Detection of caspase-3 activity was measured using the DEVD-NucView™
488 Caspase-3 Substrate (Biotium Inc, Cambridge Bioscience, Cambridge, UK)
according to manufacturer's instructions. Cells were cultured as above and
grown to 50% confluence in 35 mm sterile glass base dishes (IWAKI). Peptides
were diluted in 1 ml of pre-warmed stimulation medium and incubated with cells
to a final concentration of 10 µM for 1 h. DEVD-NucView™ 488 Caspase-3substrate was added at a final concentration of 5 µM for a further 30 min.
Nuclear staining and fluorescence was observed using a Carl Zeiss LSM 510
Meta confocal microscope.
2.9. Flow cytometry to determine annexin V and propidium
iodide staining
Annexin V staining was measured using the Annexin-V-FLUOS staining kit
(Roche, UK). 106 cells were treated with peptide, washed in Hanks balanced salt
solution, trypsinized and centrifuged at 200 ×g for 5 min. The cell pellet was
resuspended in 100 µl Annexin-V-FLUOS labelling solution containing
annexin-V-fluorescein and propidium iodide and incubated for 15 min at 15–
25 °C. Following the addition of 0.5 ml HEPES incubation buffer, fluorescence
of annexin-V-fluorescein and propidium iodide was detected in FL-1 and FL-3
channels, respectively, on a BD FACS Calibar. Unstained and untreated cells
were used to establish instrument settings and FL-1 and FL-3 cell populations
were isolated to the first log decade. Stained and untreated cells were used to
establish quadrant settings for dot plot analysis. Statistical analyses were
performed using BD Cell Quest Pro software.
2.10. Isolation of mouse liver mitochondria
Mitochondria were isolated from mouse liver (Balb/c, female, 6–8 week old,
Charles River, L'Arbresle, France) by differential centrifugations and purified
on Percoll gradients [27]. Protein concentration was determined using the micro-
BCA assay (Pierce Chemical Company, Rockford, Illinois).
2.11. Swelling, depolarization, inner membrane permeabilization and
NADH ferricyanide assays
For swelling and depolarization measurements, mitochondria (25 μg protein)
were diluted in an hypo-osmotic buffer (10 mM Tris–Mops, pH 7.4, 5 mM
succinate, 200 mM sucrose, 1 mM Pi, 10 μMEGTA, 2 μM rotenone) containing
various doses of Ca2+, mitP, MP,Mas17 or vehicle alone. Mitochondrial swelling
was immediately measured by the decrease in absorbance at 540 nm for 1000 s.
Mitochondrial depolarization was measured by the rhodamine 123 fluorescence
dequenching assay (1 μM, λexc: 485 nm, λem: 535 nm, Molecular Probes).
Mitochondria (25 μg protein), were treated with or without inducers for 30 min at
37 °C to induce the swelling. Thereafter, DTNB (0.1 mM), acetylCoA (0.3 M)
and oxaloacetate (0.5 mM) were added sequentially every 10 min and the
absorbance at 412 nm was recorded for 2300 s. For NADH ferricyanide activity
of VDAC,mitochondria (10 μg proteins) were equilibrated for 10 min at 37 °C in
the presence of inducers or vehicle thereafter 250 μM NADH was added. After
15 min of incubation, addition of 300 μM ferricyanide was used to start the
measurement of the fluorescence (λexc=360 nm; λem=465 nm). All assays
were adapted from Tarze et al. [28] for 96-well plate analysis and were performed
at 37 °C in a spectrofluorimeter (TECAN genios, TECAN, Grödig, Austria).
2.12. Cytochrome c release
Mitochondria (40 μg of protein), treated or not by CaCl2, MitP and MP, were
incubated for 30 min at 37 °C and then centrifuged at 6800 ×g for 10 min at 4 °C.
Proteins contained in the supernatants were precipitated by methanol:chloro-
form [4:1 vol/vol], suspended in Laemmli sample buffer, separated by SDS-
PAGE (15%) and transferred to PVDF membranes (Millipore, Hampshire, UK).
After 2 h incubation at 20 °C with anti-cytochrome c (BD Biosciences, Le Pont
de Clay, France), proteins were detected using the ECL method according to the
manufacturer's instructions (Amersham Pharmacia Biotech, Rockford, IL).3. Results
3.1. Peptide design
The ability of MP to form an amphipathic α−helix is a major
determinant of its biological activity. Lysyl residues at positions 4,
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cationic hydrophilic face [10]. Our initial design of mitP in-
corporated sequence permutations that were not only compatible
with the formation of an amphipathic helix, but also enhanced the
amphipathicity of MP by introducing additional lysyl residues
(Lys5, Lys8) within the hydrophilic face. This together with a
known helix promoter, α-aminoisobutyric acid (Aib), produced a
highly efficacious cytotoxic MP analogue [16]. In accordance
with this observation, chimeric mitP analogues were rationally
designed to maintain the amphipathicity of mitP. Z-Gly-RGDf-
mitP conferred a cationic charge distribution that was compatible
with an amphipathic α-helix. N-terminal blockade with Z-Gly
and the inclusion of a D isomer of Phe(f), were additional modi-
fications likely to improve the biostability of Z-Gly-RGDf-mitP.
The control peptide Z-Gly-RGEf-mitP was also included in this
study; since the conservative substitution of Glu for Asp in the
core RGD sequence prevents integrin binding. N-terminal
extension of mitP with the Fas ligand mimetic peptide WEWT
was predicted to be incompatible with the formation of an
extended amphipathic α-helix. Therefore, aminohexanoic acid
was used as a flexible linker in the chimeric sequence of WEWT
(Ahx)mitP.
To facilitate intracellular co-localization, mitP and related
chimeric analogues were synthesized by N-terminal acylation
with 6-carboxytetramethylrhodamine, to give the rhodamine-
conjugated peptide Rho-mitP or, 5-carboxyfluorescein to give
the fluorescein chimeric analogues Fluo-Gly-RGDf-mitP and
Fluo-WEWT(Ahx)mitP.
Peptides were manually synthesized employing an N-α-Fmoc
protection strategy and masses confirmed bymatrix-assisted laser
desorption ionization (MALDI) time of flight mass spectrometry
(Table 1).
3.2. Mitoparan: cytotoxicity profiles and mechanisms of
cell death
MitP promotes a concentration-dependent decrease in
U373MG cell viability [16]. To extend the temporal characterisa-
tion of the cytotoxic actions of this peptide, changes in the
viability of U373MG and ECV304 cells were analyzed over a
24 h time periodwith a peptide concentration range of 0.1–30 µM
(Fig. 1). Amaximal reduction in cell viability was achieved in 4 h
with negligible alteration in cell viability thereafter. LD50 values
(expressed as mean±S.E.M.) were taken at 24 h giving 7.92±
0.12 µM and 6.81+0.05 µM for U373MG and ECV304 re-
spectively and demonstrate dramatically increased potencies
compared to MP (LD50=26.49±0.04 µM and 30.26±0.05 µM
for U373MG and ECV304 respectively) under the same ex-
perimental conditions (Table 2).
Fig. 2A clearly indicates that inter-nucleosomal DNA frag-
mentation, as detected by in situ TUNEL staining, was evident in
both U373MG and ECV304 cells following 2 h of treatment with
mitP (10 µM). In addition, mitP (10 µM) promoted activation of
caspase-3 (Fig. 2B) in both cell lines at 1.5 h. To firmly establish
the mechanism of cell death, detection of phosphatidylserine
translocation to the outer plasma membrane, a feature of early
apoptosis, was measured by annexin-V staining and flow cyto-metry. Since necrotic cells also expose phosphatidylserine owing
to loss of membrane integrity, propidium iodide exclusion was
carried out to discriminate between apoptosis and necrosis. Ac-
cordingly, following treatment with mitP (10 µM), data clearly
show a predominant population of annexin-V positive and pro-
pidium iodide negative cells (early apoptotic) compared to the
small percentage of cells that stained for both propidium iodide
and annexin-V (necrotic) (Fig. 2C). Taken together, these data are
consistent with apoptosis as the primary mechanism of mitP-
induced cell death. On the basis of these findings, and given that
MP binds mitochondrial membranes in cell free systems to pro-
mote release of cytochrome c [8], we speculated as to whether the
observed apoptotic actions of mitP were attributable to its ability
to translocate plasma membranes and to interact with mitochon-
dria in living cellular systems. Confocal live cell imaging demon-
strated that Rho-mitP (5 µM) assumed both an outer membrane
and cytosolic distribution in U373MG cells after 30 min
(Fig. 3A). Additional live cell images following 1 h of exposure
to the peptide revealed a distinct co-localization with mitochon-
drial membranes in both U373MG and ECV304 cells (Fig. 3B).
Moreover, this intracellular redistribution was accompanied by a
loss of fluorescence associated with the plasma membrane.
Quantitative co-localization was carried out giving colocalization
coefficients for U373MG of 0.82±0.04 (channel 1; rhodamine)
and 0.91±0.04 (channel 2; fluorescein) and for ECV304 of 0.85±
0.04 (channel 1; rhodamine) and 0.75±0.08 (channel 2; fluo-
rescein). Overlap coefficients after Manders gave 0.78±0.02
and 0.74±0.01 for U373MG and ECV304, respectively.
U373MG and ECV304 cells were also treated with rhodamine-
conjugated MP (Rho-MP) under the same conditions. Confocal
live cell imaging (Fig. 3C) and quantitative analysis for U373MG
of 0.40±0.07 (channel 1; rhodamine) and 0.69±0.08 (channel 2;
fluorescein) and for ECV304 of 0.26±0.04 (channel 1; rho-
damine) and 0.21±0.06 (channel 2; fluorescein), demonstrated
weak co-localization with mitochondria. Thus compared to MP,
mitP demonstrates an increased propensity for mitochondrial
localization.
3.3. Interactions of mitoparan with isolated liver mitochondria
Isolated mouse liver mitochondria were used to investigate
direct actions of mitP on mitochondrial ultrastructure and
function. Firstly, we observed that mitP induced an increase in
mitochondrial volume, a loss of internal matrix material and
rupture of the outer membrane (Fig. 4A). The effect of mitP was
similar to the effects of Ca2+, a prototypic permeability tran-
sition inducer and to that of MP. Secondly, 2 μM mitP simul-
taneously triggered mitochondrial swelling (Fig. 4B(i)), loss of
transmembrane inner potential (ΔΨm) (Fig. 4B(ii)) and inner
membrane permeabilization (Fig. 4B(iii)). The kinetics of
swelling induced by mitP were similar to the kinetics elicited
by MP, but differed drastically from that of Ca2+. A dose-
response study demonstrated that 2 μM was optimal to induce
swelling of maximal amplitude (Fig. 4C(i)).
To gain additional insights into the molecular mechanisms
of mitochondrial alteration induced by mitP in comparison to
MP, we used several pharmacological agents known to
Fig. 3. MitP penetrates plasma membranes to co-localize with mitochondria. Cells were treated with 5 µM Rho-mitP and 200 nMMitotracker® Green FM (Molecular
Probes, Invitrogen) and viewed by confocal live cell imaging using a Carl Zeiss LSM 510 Meta. (A) At 30 min, Rho-mitP assumed both an outer membrane and
cytosolic distribution, a representative image is shown here for U373MG cells. (B) Live cell images of U373MG and ECV304 captured following 1 h peptide
exposure. Rho-mitP now assumes a predominant mitochondrial distribution. (C) MP demonstrates a decreased propensity for mitochondrial localization. Cells were
treated for 1 h with 5 µM Rho-MP and 200 nM Mitotracker®. Live cell images of ECV304 cells are shown here as a representative sample. Pixels having an intensity
above the single-labelled pixels for fluorescein (Mitotracker®) and rhodamine are indicative of co-localization. Co-localizing pixels are shown here in blue. An average
of 12 regions of interest were selected using the Carl Zeiss quantitative co-localization analysis software and co-localization coefficients were calculated from 3
separate experiments. Representative examples are shown.
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these, only the VDAC-targeting agents glutamate (GLU) [29]
and 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS)
[30], partially or totally inhibited mitP-induced mitochondrial
swelling (Fig. 4C(ii)). In contrast, cyclosporin A, an inhibitor
of the interaction between the adenine nucleotide translocator
(ANT) and cyclophilin D [31]; ATP, a ligand of the ANT; and
N-acetyl cystein (NAC) [32], an anti-oxidant, had no preven-
tive effect on mitP andMP-induced swelling. In addition, mitP-
induced swelling was unaffected by 5 mM ethylene glycol-bis(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), a
calcium chelator. These results indicate that mitochondrial
toxicity induced by mitP may be mediated by a specific inter-
action with VDAC (Fig. 4C(ii)). Significantly, the inhibition of
mitP-induced swelling was of a magnitude larger than that of
MP (+20%), suggesting an enhanced specificity of the VDAC-
mitP interaction. To test this hypothesis, we measured the
NADH ferricyanide activity of VDAC in the presence of mitP
and found that mitP exerted an inhibitory effect giving an EC50
of 1.84±0.22 μM (Fig. 4D).
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release of cytochrome c (Fig. 4E). When co-incubated for 30 min
with isolated mitochondria, mitP induced a dose-dependent re-lease of cytochrome c from the intermembrane space to the
externalmedium. This effectwas lower than that induced byCa2+,
but similar to that induced by mastoparan and correlated with a
857S. Jones et al. / Biochimica et Biophysica Acta 1783 (2008) 849–863decreased content of cytochrome c within the mitochondria.
This indicated that mitP induces a direct complete mitochondrial
membrane permeabilization process, in line with its capacity to
elicit mitochondrial apoptosis.
3.4. Apoptotic chimeric analogues of mitoparan:
Z-Gly-RGDf-mitP
Dose-dependent cytotoxicity was maintained in ECV304
and U373MG cells following N-terminal extension of mitP
with the integrin specific motif RGD. Moreover, in ECV304
cells, Z-Gly-RGDf-mitP demonstrated an enhanced potency
(1.40±0.13 µM) compared to mitP alone (6.81±0.05 µM,
P=0.0286) and the sequence variant Z-Gly-RGEf-mitP (4.71±
0.05 µM, P=0.0286) (Fig. 5A, Table 2). Similar results using
the sequence variant Z-Gly-RGEf-mitP were obtained for
U373MG cells (Table 2). To confirm the specificity of our RGD
containingmitP analogue, ECV304 cells were pre-incubated with
the integrin antagonist cyclic RGD peptide, cyclo(-RGDfV) [33].
Given that cyclo(-RGDfV) is a potent inhibitor of cell adhesion,
cells viability readings were taken at 2 h and at a competing
ligand concentraion of 300nM, conditions optimized to allow for
viability readings without cellular detachment. Addition of cyclo
(-RGDfV) reduced the potency of Z-Gly-RGDf-mitP from 6.08±
0.08 µM to 9.17±0.07 µM, P=0.05, (Fig. 5B, Table 2). Treat-
ment of U373MG cells with our integrin-targeting mitP analogue
demonstrated that Z-Gly-RGDf-mitPwasmoderatelymore potent
(LD50=4.79±0.16 µM) than mitP (LD50=7.92±0.12 µM) on
this cell line, P=0.05, (Fig. 5C, Table 2). Similarly, addition of
cyclo(-RGDfV) to U373MG cells, under the above optimized
conditions reduced the potency of Z-Gly-RGDf-mitP from 4.87±
0.83 µM to 10.27±2.5 µM (Table 2).
To confirm the mechanism of cell death both cell lines were
treated with Z-Gly-RGDf-mitP (10 µM) for 2 h and assayed for
DNA fragmentation by in situ TUNEL staining. Fig. 5D clearly
provides evidence for apoptosis as the mechanism of cell death.
Confocal live cell imaging was used to determine the sub-
cellular distribution of fluorescein-conjugated Z-Gly-RGDf-
mitP. Fig. 5E demonstrates that 5 µM Fluo-Gly-RGDf-mitP
translocated to the intracellular environment of both ECV304
and U373MG cells.Fig. 4. Interaction of mitP with isolated mitochondria. (A) Morphology of mouse live
mitP or MP for 30 min and their morphology was studied by transmission electronic m
induced similar alterations to Ca2+ and MP, as was observed by swelling, membran
(Co.). Magnitude: ×12 000. (B) Swelling, loss of transmembrane inner potential (Δ
mitP. Isolated mitochondria were treated with Ca2+, mitP, MP, the inactive MP ana
measure the swelling of the mitochondrial matrix (i). (ii) Mitochondria were incub
Rh123. Fluorescence was recorded for 1500 s. (iii) Permeabilization of the inner mito
measured at 412 nm for 2300 s. Experiments were repeated three times in triplicate.
mitP and pharmacological inhibition. Increasing concentrations of mitP were added an
for 1000 s. The effect of 50 μMCa2+ was normalized to 100% (i). Various concentratio
DIDS, were added to mitochondria 2 min before mitP or MP and swelling was measur
were repeated three times in triplicate. (D) Inhibition of VDAC by mitP. NADH f
concentration-dependent decrease in enzyme activity in response to mitP allowed for
dose-response function of GraphPad Prism software. (E) Release of cytochrome c f
30 min at 37 °C by indicated agents and centrifuged. Supernatants and pellets, corre
western-blotting for the presence of cytochrome c (Cyt c).3.5. Apoptotic chimeric analogues of mitoparan: WEWT(Ahx)
mitP
Both cell lines were treated with our mitP analogue which
incorporated the Fas ligand mimetic WEWT and assayed for
cytotoxicity. Fig. 6A and Table 2 show that WEWT(Ahx)mitP
(LD50=4.44±0.04 µM) was moderately more potent than mitP
(LD50=6.81±0.05 µM) in ECV304 cells, P=0.05. Reports
indicate that U373MG cells are resistant to Fas ligand-induced
apoptosis (extrinsic pathway) through an observed down re-
gulation of caspase-8 [34] and a reduced cell surface expression
of Fas [35]. Similarly, data from our laboratory indicates that
following 24 h treatment with tumour necrosis factor-α (TNF-
α; 400 ng/ml), U373MG cell viability is relatively unaltered at
90.0%, whereas, cell viability is reduced to 66.0% under the
same conditions in ECV304 cells (P=0.0001). A dramatically
enhanced potency for WEWT(Ahx)mitP in ECV304 cells
(LD50=4.44±0.04 µM) was observed compared to U373MG
(LD50=28.10±0.03 µM), P=0.05, (Fig. 6B, Table 2). More-
over, the potency of WEWT(Ahx)mitP in U373MG cells was
severely reduced compared to the parent cytotoxin mitP, on
the same cell line (LD50=7.92±0.12 µM), P=0.05, (Table 2).
As with the integrin targeting mitP analogue, apoptosis was
confirmed as the mechanism of cell death for both cell lines
(Fig. 6E) and cellular penetration was confirmed by confocal
live cell imaging (Fig. 6F).
3.6. Mitoparan and its chimeric analogues induce cell death
independently of the extrinsic apoptotic pathway
Reports that U373MG cells are resistant to Fas-mediated
apoptosis may offer a simple explanation for the observed
enhancement in potency of WEWT(Ahx)mitP in ECV304 cells
compared to U373MG and also suggests that activation of the
extrinsic apoptotic pathway may account in part, for the cyto-
toxic mechanisms employed by WEWT(Ahx)mitP in ECV304
cells. Moreover, TNF-α (40 ng/ml) induced a statistically
significant increase in caspase-8 activity in ECV304 cells of
1.60 fold compared to 1.10 fold in U373MG cells (P=0.0159)
(Fig. 6C). However, Fig. 6C also indicates that WEWT(Ahx)
mitP (10 µM, 30 µM) did not activate caspase-8 in ECV304r mitochondria treated with mitP. Isolated mitochondria were treated with Ca2+,
icroscopy (TEM) and compared with untreated control preperations (Co). MitP
e rupture and loss of internal material in comparison to untreated mitochondria
Ψm) and permeabilization of the inner mitochondrial membrane in response to
logue Mas17 or control and absorbance at 540 nm was recorded for 1000 s to
ated under the same conditions but in the presence of a ΔΨm-sensitive probe,
chondrial membrane. Isolated mitochondria were treated as in (i) and absorbance
(C) Concentration-dependent increase in mitochondrial swelling in response to
d mitochondrial swelling was evaluated by the decrease in absorbance at 540 nm
ns of inhibitors, 5 μMCsA, 0.5 mMATP, 5 mMNAC, 0.5 mMGLU and 25 μM
ed. The effects of 2 μMmitP andMP were normalized to 100% (ii). Experiments
erricyanide reductase activity was used as an indicator of VDAC function. A
determination of an EC50 value for mitP. Data were analyzed using the sigmoidal
rom the intermembrane space. Mitchondria (25 μg of proteins) were treated for
sponding the released fraction and the pelleted mitochondria, were analyzed by
858 S. Jones et al. / Biochimica et Biophysica Acta 1783 (2008) 849–863cells. Similarly, WEWT(Ahx)mitP failed to activate caspase-8
in U373MG cells. Both cell lines were resistant to activation of
caspase-8 by mitP (Fig. 6C). On the basis that after 30 min,
Rho-mitP assumed both an outer membrane and intracellulardistribution, activation of caspase-8 was measured after 30 min
under the above conditions. To refine and extend the above
findings, activation of caspase-8 was measured up to 4 h
following the treatment of ECV304 cells with WEWT(Ahx)
859S. Jones et al. / Biochimica et Biophysica Acta 1783 (2008) 849–863mitP and mitP. Neither peptide induced stimulation of caspase-8
in this cell line (Fig. 6D).
4. Discussion
Previously, MP has been considered as a non-specific inducer
of plasma membrane pore formation. Data presented herein
clearly shows that our novel MP analogue, mitP, exhibits both
cell penetrant, mitochondriotoxic and apoptogenic properties,
features that could be of potential therapeutic utility. Moreover,
we have demonstrated that mitP can be modified to incorporate
tissue-specific address motifs, constructs that not only maintain,
but enhance the potency of mitP alone.
4.1. Mechanisms of mitoparan-mediated cell death
Fig. 3 clearly shows that at 30 min, Rho-mitP (5 µM) as-
sumed an outer cell membrane and cytosolic distribution in
living cells. After 1 h, Rho-mitP redistributed to co-localize with
mitochondria, a feature that is not shared by its parent compound
Rho-MP. A prerequisite to the execution of apoptosis is the
caspase cascade, a series of cysteinyl aspartyl proteases that
converge with the activation of caspase-3. Fig. 2 indicates that
following 1.5 h, mitP (10 µM) induced activation of caspase-3 in
both U373MG and ECV304 cells. Moreover, we have con-
clusively demonstrated that in cell free systems, mitP induces
swelling, depolarization and permeabilization of the inner
mitochondrial membrane. We suggest that, in living cellular
systems, mitP induces apoptosis by targeting and interacting
with mitochondrial membranes. Subsequently, enhanced mem-
brane permeability augments the release of cytochrome c which
consequentially leads to activation of the caspase cascade.
Furthermore, given that both cell lines were resistant to the
activation of caspase-8 by mitP and we observed apoptotic cell
death in U373MG cells, a line that is apparently resistant to Fas-
mediated apoptosis [34], it may be concluded that mitP does not
induce apoptosis via the extrinsic pathway and death receptor
mimicry as has been tentatively postulated previously for MP
[9].
MitP has clearly demonstrated an enhanced cytotoxic po-
tency (LD50=7.92 µM and 6.81 µM for U373MG and ECV304,
respectively) compared to MP (LD50=26.49 µM and 30.26 µM
for U373MG and ECV304, respectively) (Table 2), an ob-
servation that is more than likely reflected by its improved
penetrative and mitochondrial localizing capacities in addition
to its ability to alter mitochondrial membrane permeabilityFig. 5. Z-Gly-RGDf-mitP: Cytotoxicity profiles and intracellular translocation. (A) Z
and the sequence variant Z-Gly-RGEf-mitP. ECV304 cells were exposed to increasing
MTT conversion and expressed as a percentage of those cells treated with vehicle
in triplicate. (B) Specificity of Z-Gly-RGDf-mitP for integrins as confirmed by antago
(-RGDfV) for 20 min prior to the addition of increasing concentrations of Z-Gly-RG
enhances the potency of mitP in U373MG. Cells were treated with peptides for 24
ECV304 and U373MG as confirmed by in situ TUNEL assay. Cells were exposed to
Fig. 2A. Bars are 20 µm. (E) Fluo-Gly-RGDf-mitP translocates plasma membranes of
was captured 45 min after the addition of 5 µM fluorescein-labelled peptide, shown
merged with images taken under transmission differential interference contrast micrthrough an enhanced co-operation with a protein of the per-
meability transition pore complex (PTPC), VDAC. Indeed,
previous reports that claim MP to be a potent facilitator of the
permeability transition pore opening [6], show that at concen-
trations above 1 µM, MP-induced opening of permeability
transition pores is insensitive to specific inhibition of PTP pro-
teins and only at concentrations below 1 µM does MP facilitate
pore opening which is susceptible to PTP protein inhibition.
Though this study was largely restricted to observations using
cyclosporin A, an inhibitor of the interaction between cy-
clophilin D and ANT, an observation that we also report, unlike
MP, mitP clearly facilitates mitochondrial membrane perme-
ability through specific interaction with VDAC even at con-
centrations above 1 µM.
As a point of conjecture, our data demonstrate an apoptotic
response to acute chemical toxicity, a response that does not
strictly concur with the true definition of programmed cell
death, i.e. a tightly controlled selective elimination of cells that
threaten organ homeostasis. But rather, by the very nature of its
cell penetrant properties, mitP exploits intracellular apoptotic
machinery to ultimately promote induction of the caspase cas-
cade. Interestingly, following tissue injury or chemical insult,
both features of apoptosis and necrosis are evident, an ob-
servation that has fuelled doubt as to apoptosis being the sole
mechanism of cell death under these circumstances [36]. As a
consequence, the author Lemasters proposes the introduction of
a new definition of cell death for cells showing signs of apo-
ptosis following acute chemical toxicity, termed necrapoptosis
[36]. Such a definition promotes a less rigid and probably more
accurate description of cell death to chemical insults and is
not confined by the extreme polemics of either apoptosis or
necrosis.
4.2. Therapeutic utility of mitochondriotoxic CPP
MitP penetrates plasma membranes to bind intracellular
targets that promote cellular apoptosis. Such mitochondriotoxic
properties provide advancements in the design of novel and
potent cell penetrant inducers of apoptosis. One of the major
drawbacks to the clinical relevance of CPPs has lain in their
susceptibility to proteolysis. However, various strategies have
been successfully employed, to combat premature degradation,
such as incorporation of D-amino acids and retroinverso trans-
formation [37]. So, since the first serendipitous discovery of
CPPs some 20 years ago, we are beginning to embrace an era
of CPPs in drug development. For instance, cell penetrant-Gly-RGDf-mitP demonstrates an enhanced cytotoxic potency compared to mitP
concentrations of peptides (0.1–30 µM) for 24 h. Cell viability was measured by
(medium) alone. Data points are mean±S.E.M. from 3 experiments performed
nism with cyclo(-RGDfV). ECV304 cells were pre-incubated with 300 nM cyclo
Df-mitP for a further 2 h. Data are expressed as above. (C) Z-Gly-RGDf-mitP
h and data are expressed as above. (D) Z-Gly-RGDf-mitP induces apoptosis of
10 µM peptide for 2 h and treated as in Fig. 2A. Control data are also shown in
ECV304 (bar 5 µm) and U373MG (bar 10 µm) cells. Live confocal cell imaging
here in green. Cellular distributions of Fluo-Gly-RGDf-mitP are presented here
oscopy.
860 S. Jones et al. / Biochimica et Biophysica Acta 1783 (2008) 849–863constructs for the treatment of cardiac ischaemia are now en-
tering clinical trials [38], an advancement that is of no doubt
testament to their clinical applicability.Delivered as message address constructs, our apoptotic chi-
meric mitP analogues demonstrated enhanced potencies com-
pared to the parent cytotoxin alone and are thus of potential
861S. Jones et al. / Biochimica et Biophysica Acta 1783 (2008) 849–863clinical relevance. Moreover, and as stated above, by their very
nature, peptides are hydrolyzed readily by endopeptidases.
However, this apparent drawback would appear to be advan-
tageous in the case of aggressive malignancies were in situ anti-
tumour drug delivery is currently being practiced, demonstrat-
ing low toxicity to nearby tissues and avoidance of multiple
drug resistance. In addition, tumour specific targeting by pep-
tidyl address motifs could enhance the selectivity of drug
delivery leading to a probable reduction in non-selective side-
effects.
Previous reports show MP, as part of a tumour targeting
liposomal complex, to be effective at concentrations of 25 µM
[15]. In comparison, we demonstrate an enhanced potency of
mitP on ECV304 and U373MG, with LD50s of 6.81 µM and
7.92 µM respectively and more dramatically so as a sychnologic
construct with the RGD address motif, giving LD50s of 1.40 µM
and 4.79 µM. Moreover, the enhanced potency demonstrated
by Z-Gly-RGDf-mitP on ECV304 of 1.40 µM is easily
achievable in vivo. Thus, we have a highly potent mitochon-
driotoxic CPP and a structure that easily incorporates into a
tissue specific construct without impacting upon the bioactivity
of the cytotoxin.
Recent findings have indicated that some CPPs are excluded
from mitochondrial matrices [39]. Nevertheless, such studies
have restricted their observations to limited numbers of CPPs
such as the polycationic sequences derived from the HIV-1
transactivator protein, Tat(48–60) and the homeodomain of the
homeoprotein Antennapaedia, penetratin (43–58). Furthermore,
it is now apparent that there is no uniform mechanism of CPP
uptake. Diverse mechanisms include both endocytotic and non-
endocytotic mechanisms, energy dependent and translocation
occurring at 4 °C and in the absence of ATP. Also, chimeric
CPP, consisting of CPP and cargo can adopt quite different
mechanisms of uptake to that of the parent CPP [40].
The degree of endosomal sequestration appears to be pro-
blematic when delivering CPP or CPP-conjugated cargo and
is a matter still open to debate. However, studies that clearly
show a robust biological response, as is the case with our mito-
chondriotoxic CPP, also demonstrate avoidance of endo-
somal entrapment. In addition, conclusions reached showing
that CPPs are not internalized into mitochondria were based
not only on live cell imaging colocalization studies but also
on isolated mitochondria [39]. However data presented here, for
mitP, clearly show mitochondrial targeting and internalization in
both isolated systems and live cell imaging, respectively.Fig. 6. WEWT(Ahx)mitP: Cytotoxicity profiles and intracellular translocation. (A) N
the cytotoxic potency of mitP in ECV304 cells. (B) The Fas-mediated apoptotic resi
compared to ECV304. Both cell lines were exposed to increasing concentrations of p
and expressed as a percentage of those cells treated with vehicle (medium) alone
(C) WEWT(Ahx)mitP (10 µM, 30 µM) does not activate caspase-8 in ECV304 or U3
parent cytotoxin mitP. Cells were treated with peptide for 30 min and assayed for c
recombinant caspase-8 enzyme (R & D Systems) was used as a positive control and
Asterisks indicate significantly different means, P=0.0159. (D) Temporal analysis up
and mitP (10 µM) does not activate caspase-8. (E) WEWT(Ahx)mitP induces apopto
exposed to 10 µM peptide for 2 h and treated as in Fig. 2A. Control data are also sho
membranes of ECV304 and U373MG cells. Live confocal cell imaging was capture
green. Cellular distributions of Fluo-WEWT(Ahx)mitP are presented here merged wi
Bars are 10 µm.4.3. Differential pharmacodynamic parameters of chimeric
mitoparan analogues
Pre-incubation of ECV304 cells with the integrin antagonist
cyclo(-RGDfV) reduced the cytotoxic potency of Z-Gly-RGDf-
mitP and indicated specificity of the chimeric peptide Z-Gly-
RGDf-mitP for integrin receptors expressed on ECV304.
Similarly, the reduced potency shown by the sequence variant
Z-Gly-RGEf-mitP, further suggests integrin-mediated binding for
the Z-Gly-RGDf-mitP peptide.
Z-Gly-RGDf-mitP proved to be the most potent of all ana-
logues tested. The ability of this chimera to specifically target
integrins, leading to an increased propensity for plasma mem-
brane insertion, may account for this observation. Alternatively,
Z-Gly-RGDf-mitP was rationally designed to maintain the
amphipathicity of mitP. Moreover, the additional cationic charge
provided by Arg2 of the RGD motif would increase amphipathi-
city, thus leading to enhanced cellular penetration. Furthermore,
N-terminal blockade with Z-Gly, an amidated C-terminal and
incorporation of DPhe, will improve the biostability of this chi-
mera. Thus, protease resistance may also contribute to the en-
hanced bioactivity of this chimeric analogue.
The enhanced potency of WEWT(Ahx)mitP with ECV304
cells compared to U373MG was considered to be a consequence
of U373MG being resistant to Fas-mediated apoptosis [34].
An observation that led to the assumption that this mitP analo-
gue was mediating apoptotic events in ECV304 cells, in part,
through the extrinsic cell death pathway. However, WEWT(Ahx)
mitP did not activate caspase-8 in ECV304 cells. Likewise,
WEWT(Ahx)mitP did not activate caspase-8 in U373MG cells. It
is significant that U373MG cells are mutant p53 glioma cells. Not
only is Fas-mediated apoptosis compromised at the level of
caspase-8 [34], but in p53 deficient cell lines, Fas expression is
diminished both at the level of transcription and the fully trans-
lated cell membrane protein [35]. A decreased cell surface ex-
pression of Fas in U373MG cells may account for the reduced
potency observed for WEWT(Ahx)mitP (LD50=28.10 µM) com-
pared to mitP (LD50=7.92 µM) on U373MG cells and WEWT
(Ahx)mitP on ECV304 cells (LD50=6.81 µM). This observation
confirms cell surface markers/binding sites as a pre-requisite for
the bioactivity of our addressed apoptotic chimeric analogues. Not
only is the potency of WEWT(Ahx)mitP reduced in cells where
Fas is compromised but, as is the case withWEWT(Ahx)mitP, the
potency of the parent cytotoxin (mitP) is lessened. This latter
feature is advantageous when cell-specific delivery is required.-terminal extension of mitP with WEWT via an Ahx linker moderately enhances
stant cell line U373MG demonstrates a decreased potency to WEWT(Ahx)mitP
eptides (0.1–30 µM) for 24 h. Cell viability was measured by MTT conversion
. Data points are mean±S.E.M. from 3 experiments performed in triplicate.
73MG cells, whilst both cell lines are resistant to activation of caspase-8 by the
aspase-8 activity using the Caspase-8 Colorimetric Assay (R & D Systems). A
TNF-α (exposure time of 24 h) as a receptor-mediated activator of caspase-8.
to 4 h, shows that treatment of ECV304 cells with WEWT(Ahx)mitP (10 µM)
sis of ECV304 and U373MG as confirmed by in situ TUNEL assay. Cells were
wn in Fig. 2A. Bars are 20 µm. (F) Fluo-WEWT(Ahx)mitP translocates plasma
d 45 min after the addition of 5 µM fluorescein-labelled peptide, shown here in
th images taken under transmission differential interference contrast microscopy.
862 S. Jones et al. / Biochimica et Biophysica Acta 1783 (2008) 849–863We conclude that the mitochondriotoxic properties of mitP,
and the improved pharmacodynamic parameters of chimeric
mitP analogues, offer utility for the study and therapeutic in-
duction of apoptosis in human cancer cells.
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